knowledge -WSS

knowledge

author：hotspot 2025-09-28 00:50:33 - browse：8696

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： J&J to emphasize cancer drugs, stop much of its vaccine research

WSS

Manchin plays down potential 3rd

Flagship Pioneering launches a new biotech in two countries

J&J to emphasize cancer drugs, stop much of its vaccine research

House passes resolution saying Israel isn't a 'racist or apartheid state'

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

A strong 6.5

focus

knowledge

hotspot

Supreme Court strikes down use of affirmative action

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

State Dept. review finds Biden bears some blame for Afghanistan failures

Biden administration sends mixed signals on US soldier who crossed into North Korea

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

30 years of 'Listening to Prozac'

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Lack of darker skin in textbooks, journals harms patients of color

At least 13 dead in Texas as scorching temps continue

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Wikipedia

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

With clinical trial data readouts, here's how to spot spin

What we know about the American soldier detained in North Korea

Johnson & Johnson sues to stop Medicare negotiation

Robert Kennedy Jr.'s presidential campaign attracts GOP

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

entertainment

entertainment

knowledge

entertainment